Loading...
The effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase 3 SQUIRE trial.
Reck, M Socinski, M Luft, A Szczęsna, A Dediu, M Ramlau, R Losonczy, G Molinier, O Schumann, C Gralla, R
Reck, M
Socinski, M
Luft, A
Szczęsna, A
Dediu, M
Ramlau, R
Losonczy, G
Molinier, O
Schumann, C
Gralla, R
Citations
Altmetric:
Abstract
Necitumumab, a second-generation, recombinant human immunoglobulin G1 epidermal growth factor receptor antibody in the phase 3 SQUIRE trial (NCT00981058), increased survival benefit for patients randomized to receive necitumumab plus gemcitabine-cisplatin compared with those who received gemcitabine-cisplatin. Here we characterize health-related quality of life (HRQoL) and tolerability results.
Description
Date
2016-03-12
Publisher
Collections
Keywords
Type
Article
Citation
The effect of necitumumab in combination with gemcitabine plus cisplatin on tolerability and on quality of life: results from the phase 3 SQUIRE Trial. 2016: J Thorac Oncol